Click for best price
Pulmonary Arterial Hypertension PAH Drugs Market Size, Share 2022
This report contains market size and forecasts of Pulmonary Arterial Hypertension (PAH) Drugs in global, including the following market information:
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Pulmonary Arterial Hypertension (PAH) Drugs companies in 2021 (%)
The global Pulmonary Arterial Hypertension (PAH) Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Inhalation Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs include Pfizer, Glaxosmithkline, Novartis, United Therapeutics, AstraZeneca, Merck, Bayer Healthcare, Actelion Pharmaceuticals and Daiichi Sankyo, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Pulmonary Arterial Hypertension (PAH) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pulmonary Arterial Hypertension (PAH) Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment Percentages, by Type, 2021 (%)
Inhalation
Injectables
Oral Administration
Global Pulmonary Arterial Hypertension (PAH) Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Other
Global Pulmonary Arterial Hypertension (PAH) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pulmonary Arterial Hypertension (PAH) Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Pulmonary Arterial Hypertension (PAH) Drugs revenues share in global market, 2021 (%)
Key companies Pulmonary Arterial Hypertension (PAH) Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Pulmonary Arterial Hypertension (PAH) Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Glaxosmithkline
Novartis
United Therapeutics
AstraZeneca
Merck
Bayer Healthcare
Actelion Pharmaceuticals
Daiichi Sankyo
Northern Therapeutics
Aires Pharmaceuticals
Arena Pharmaceuticals
Berlin Cures
Eiger BioPharmaceuticals
Reata Pharmaceuticals
| Report Attributes |
Report Details |
| Report Title |
Pulmonary Arterial Hypertension (PAH) Drugs Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
111 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Pulmonary Arterial Hypertension (PAH) Drugs Overall Market Size
2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size: 2021 VS 2028
2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales: 2017-2028
3 Company Landscape
3.1 Top Pulmonary Arterial Hypertension (PAH) Drugs Players in Global Market
3.2 Top Global Pulmonary Arterial Hypertension (PAH) Drugs Companies Ranked by Revenue
3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Companies
3.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Companies
3.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Pulmonary Arterial Hypertension (PAH) Drugs Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Players in Global Market
3.8.1 List of Global Tier 1 Pulmonary Arterial Hypertension (PAH) Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Markets, 2021 & 2028
4.1.2 Inhalation
4.1.3 Injectables
4.1.4 Oral Administration
4.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts
4.2.1 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2022
4.2.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2023-2028
4.2.3 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
4.3 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts
4.3.1 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2022
4.3.2 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2023-2028
4.3.3 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
4.4 By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Other
5.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts
5.2.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2022
5.2.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2023-2028
5.2.3 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
5.3 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts
5.3.1 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2022
5.3.2 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2023-2028
5.3.3 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
5.4 By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2021 & 2028
6.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue & Forecasts
6.2.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2022
6.2.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2023-2028
6.2.3 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
6.3 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales & Forecasts
6.3.1 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2022
6.3.2 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2023-2028
6.3.3 By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028
6.4.2 By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2028
6.4.3 US Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.4.4 Canada Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.4.5 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028
6.5.2 By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2028
6.5.3 Germany Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.5.4 France Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.5.5 U.K. Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.5.6 Italy Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.5.7 Russia Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.5.8 Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.5.9 Benelux Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028
6.6.2 By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2028
6.6.3 China Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.6.4 Japan Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.6.5 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.6.6 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.6.7 India Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028
6.7.2 By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2028
6.7.3 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.7.4 Argentina Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, 2017-2028
6.8.3 Turkey Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.8.4 Israel Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.8.5 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
6.8.6 UAE Pulmonary Arterial Hypertension (PAH) Drugs Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Pfizer
7.1.1 Pfizer Corporate Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.1.5 Pfizer Key News
7.2 Glaxosmithkline
7.2.1 Glaxosmithkline Corporate Summary
7.2.2 Glaxosmithkline Business Overview
7.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.2.5 Glaxosmithkline Key News
7.3 Novartis
7.3.1 Novartis Corporate Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.3.5 Novartis Key News
7.4 United Therapeutics
7.4.1 United Therapeutics Corporate Summary
7.4.2 United Therapeutics Business Overview
7.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.4.5 United Therapeutics Key News
7.5 AstraZeneca
7.5.1 AstraZeneca Corporate Summary
7.5.2 AstraZeneca Business Overview
7.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.5.5 AstraZeneca Key News
7.6 Merck
7.6.1 Merck Corporate Summary
7.6.2 Merck Business Overview
7.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.6.5 Merck Key News
7.7 Bayer Healthcare
7.7.1 Bayer Healthcare Corporate Summary
7.7.2 Bayer Healthcare Business Overview
7.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.7.5 Bayer Healthcare Key News
7.8 Actelion Pharmaceuticals
7.8.1 Actelion Pharmaceuticals Corporate Summary
7.8.2 Actelion Pharmaceuticals Business Overview
7.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.8.5 Actelion Pharmaceuticals Key News
7.9 Daiichi Sankyo
7.9.1 Daiichi Sankyo Corporate Summary
7.9.2 Daiichi Sankyo Business Overview
7.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.9.5 Daiichi Sankyo Key News
7.10 Northern Therapeutics
7.10.1 Northern Therapeutics Corporate Summary
7.10.2 Northern Therapeutics Business Overview
7.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.10.5 Northern Therapeutics Key News
7.11 Aires Pharmaceuticals
7.11.1 Aires Pharmaceuticals Corporate Summary
7.11.2 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Business Overview
7.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.11.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.11.5 Aires Pharmaceuticals Key News
7.12 Arena Pharmaceuticals
7.12.1 Arena Pharmaceuticals Corporate Summary
7.12.2 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Business Overview
7.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.12.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.12.5 Arena Pharmaceuticals Key News
7.13 Berlin Cures
7.13.1 Berlin Cures Corporate Summary
7.13.2 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Business Overview
7.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.13.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.13.5 Berlin Cures Key News
7.14 Eiger BioPharmaceuticals
7.14.1 Eiger BioPharmaceuticals Corporate Summary
7.14.2 Eiger BioPharmaceuticals Business Overview
7.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.14.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.14.5 Eiger BioPharmaceuticals Key News
7.15 Reata Pharmaceuticals
7.15.1 Reata Pharmaceuticals Corporate Summary
7.15.2 Reata Pharmaceuticals Business Overview
7.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Major Product Offerings
7.15.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue in Global (2017-2022)
7.15.5 Reata Pharmaceuticals Key News
8 Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, Analysis
8.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity, 2017-2028
8.2 Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Pulmonary Arterial Hypertension (PAH) Drugs Supply Chain Analysis
10.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Value Chain
10.2 Pulmonary Arterial Hypertension (PAH) Drugs Upstream Market
10.3 Pulmonary Arterial Hypertension (PAH) Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Pulmonary Arterial Hypertension (PAH) Drugs in Global Market
Table 2. Top Pulmonary Arterial Hypertension (PAH) Drugs Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Companies, 2017-2022
Table 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Companies, (K Pcs), 2017-2022
Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Price (2017-2022) & (USD/Pcs)
Table 8. Global Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
Table 9. List of Global Tier 1 Pulmonary Arterial Hypertension (PAH) Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Pulmonary Arterial Hypertension (PAH) Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2017-2022
Table 15. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2023-2028
Table 16. By Application ? Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2017-2022
Table 20. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2023-2028
Table 21. By Region ? Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2017-2022
Table 25. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), 2023-2028
Table 26. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2017-2022
Table 29. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2023-2028
Table 30. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2017-2022
Table 33. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2023-2028
Table 34. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2017-2022
Table 37. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2023-2028
Table 38. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2017-2022
Table 41. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2023-2028
Table 42. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2017-2022
Table 45. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, (K Pcs), 2023-2028
Table 46. Pfizer Corporate Summary
Table 47. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 48. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 49. Glaxosmithkline Corporate Summary
Table 50. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 51. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 52. Novartis Corporate Summary
Table 53. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 54. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 55. United Therapeutics Corporate Summary
Table 56. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 57. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 58. AstraZeneca Corporate Summary
Table 59. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 60. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 61. Merck Corporate Summary
Table 62. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 63. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 64. Bayer Healthcare Corporate Summary
Table 65. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 66. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 67. Actelion Pharmaceuticals Corporate Summary
Table 68. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 69. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 70. Daiichi Sankyo Corporate Summary
Table 71. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 72. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 73. Northern Therapeutics Corporate Summary
Table 74. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 75. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 76. Aires Pharmaceuticals Corporate Summary
Table 77. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 78. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 79. Arena Pharmaceuticals Corporate Summary
Table 80. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 81. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 82. Berlin Cures Corporate Summary
Table 83. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 84. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 85. Eiger BioPharmaceuticals Corporate Summary
Table 86. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 87. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 88. Reata Pharmaceuticals Corporate Summary
Table 89. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Offerings
Table 90. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 91. Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)
Table 92. Global Pulmonary Arterial Hypertension (PAH) Drugs Capacity Market Share of Key Manufacturers, 2020-2022
Table 93. Global Pulmonary Arterial Hypertension (PAH) Drugs Production by Region, 2017-2022 (K Pcs)
Table 94. Global Pulmonary Arterial Hypertension (PAH) Drugs Production by Region, 2023-2028 (K Pcs)
Table 95. Pulmonary Arterial Hypertension (PAH) Drugs Market Opportunities & Trends in Global Market
Table 96. Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers in Global Market
Table 97. Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints in Global Market
Table 98. Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials
Table 99. Pulmonary Arterial Hypertension (PAH) Drugs Raw Materials Suppliers in Global Market
Table 100. Typical Pulmonary Arterial Hypertension (PAH) Drugs Downstream
Table 101. Pulmonary Arterial Hypertension (PAH) Drugs Downstream Clients in Global Market
Table 102. Pulmonary Arterial Hypertension (PAH) Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Segment by Type
Figure 2. Pulmonary Arterial Hypertension (PAH) Drugs Segment by Application
Figure 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. Pulmonary Arterial Hypertension (PAH) Drugs Sales in Global Market: 2017-2028 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2021
Figure 9. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
Figure 10. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
Figure 11. By Type - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Pcs), 2017-2028
Figure 12. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
Figure 13. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
Figure 14. By Application - Global Pulmonary Arterial Hypertension (PAH) Drugs Price (USD/Pcs), 2017-2028
Figure 15. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
Figure 16. By Region - Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
Figure 17. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
Figure 18. By Country - North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
Figure 19. US Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
Figure 24. Germany Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. France Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
Figure 33. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. India Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
Figure 39. By Country - South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
Figure 40. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share, 2017-2028
Figure 44. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$, Mn), 2017-2028
Figure 48. Global Pulmonary Arterial Hypertension (PAH) Drugs Production Capacity (K Pcs), 2017-2028
Figure 49. The Percentage of Production Pulmonary Arterial Hypertension (PAH) Drugs by Region, 2021 VS 2028
Figure 50. Pulmonary Arterial Hypertension (PAH) Drugs Industry Value Chain
Figure 51. Marketing Channels
